PAK1 ameliorates tamoxifen resistance in breast cancer by phosphorylating other target substrates like Aurora A kinase [33], C-Terminal Binding Protein (CtBP) [9], and ErbB3-binding protein 1 (EBP1) [34]. Here, PA2G4 is linked to breast carcinoma.